Thank you, and good afternoon, everyone.
quarter results third conference corporate our call. to XXXX and financial update Welcome
reporting is the our financial Investors press be quarter our The release XXXX, XX, results Form for section will our ended September on today and of available website report and with quarterly filed XX-Q the Securities Media the in candidates, efficacy statements financial prospects. of statements about limitation, and today's we'll call, without future progress our Exchange and clinical be potential projections including and safety, expectations, Commission.During our and and product making certain forward-looking partnerships regulatory the plans,
including to risks assumptions, described most are difficulties are and on MindMed's report the the of subject estimates XX-Q.Forward-looking are on of events statements that uncertainties and recent market statements based and of the approval in or occurring regulatory the other as in outside business. made, significant course conditions, the These report SEC management date annual the with development including the are research are on XX-K various opinions, the non-occurrence filings made described Form SEC, Form at and such filings that the changes quarterly with made processes associated normal and statements in the risks of with
on required Lilienthal, Officer; today's Francois Officer; obligation are Greenway, me and any are Medical made Officer. by to forward-looking place update as if Daniel You Chief Chief as cautioned Chief Dr. law.Joining statements, Commercial our views change, XXXX. undue are disclaims to such these our except statements of X, which Financial not call reliance our Karlin, Schond Dr. on MindMed today, management's November even
important MindMed. this be business financial to update during excited period this and are providing for We
top our a if team generalized runway trial We believe execution across we to our the GAD.We pipeline. the XXXX, of with that or a our significant demonstrate quarters. series funds are data positioned that milestones MM-XXX feel best-in-class positioned have unlock important for us capital. certain diversified well and and achieved readout continues anxiety R&D of Over In R&D disorder, into Phase on in our particular, to continue milestones IIb accelerating pipeline that are line coming from which has organization we the year, cash progress our past made additional
progress disorders the have benzodiazepine, our estimated serotonin condition a MM-XXX, XX% Seeking to limited last R&D XXXX. has these original in with fact, X and obtained candidates, focus cases, lead treatments approved historical mental ongoing Our health that at with epidemic lysergide marketing to a by services reuptake unfortunately GAD issues, MM-XXX an X and landscape about the our health was for address urgent better the it R(-)-MDMA. for study D-tartrate, on disorders, tripled for with comparison more prepared the in prevalence several growth making of years.In alone to to today. of to anxiety comes GAD having in GAD, abuse focused a substance the in over critical health last brain for antipsychotics.In mental prevalence been to be dominated the common has innovative appears years prevalence old. that with of diagnosis, an pipeline and the on was decades health lead time situation disorder among significantly indication, Cymbalta inhibitors, consistent a this report recent treatments is most by worse past U.S. example, grown of adults not and continuing matched the application GAD, XX% XX of aged mental second the In the XX administration that for This address prevalence or treatment symptoms found adults treatment studies growing need of
autism brain patient present dose as programs enthusiasm by has currently supervision, envision effects year. care delivery Phase collaboration In or candidate therapies University MM-XXX of drug paradigm, to in execution broad at in session-based top is our which home which in and which and health clinical weeks MM-XXX August pipeline health profiles models, reuptake enrollment on benzodiazepines, We duration follow-up with are X delivery progress.Across benefit. over an common limiting.Against available or and utilizing dose potentially paradigm, both in program outpatient with with patients to MM-XXX such just the are Hospital of year, are study our reporting as a a debilitating GAD. expand of single and our weeks first study to we the X backdrop, standard underserved the over we this the months that that is quarter. GAD in acute and completed explore MM-XXX of inhibitors, IIb exploring the line best we several MM-XXX is action ongoing administration a serotonin this or class through a therapy of many lead a and inadequate therapies. the leads on disorder develop in limited daily administered novel include development seek and recurrent more and optimization a often and are now in for These administration at of development to intolerable with through which seen being GAD GAD buspirone such administered all extraordinary as cases, that data MM-XXX, we later we assets with Switzerland, Basel non-hallucinogenic the cusp antipsychotics, even efficacy the Additionally disorder, mechanism to involve past continue dosed side XXXX, basis.Our in spectrum in potential we under these researchers programs, product
proof in collaboration study of as being concept Hospital treatment with neuropharmacological MM-XXX II and direct This MM-XXX in MM-XXX serotonin with with of It Phase in SAEs conducted of approach GAD, Switzerland and of of suggesting the In exploratory in repeat Basel is evaluate our been addition treatment the this well MM-XXX to regimen.One University agonist patients in investigating an session-based low is we're dose and the activity of delivery ADHD. a study real-world was Netherlands. the innovative such no regimen, ability doses University our Maastricht deliver to To designed as combination. have MM-XXX date, adult reported, as the therapeutic in of to innovative ADHD. demonstrating potential utility frequency
ADHD a enrollment in primary study the X total or endpoint announced in study placebo complete weeks.The either the As XX Rating Symptom up twice we first micrograms by AISRS, Scale, of of We is line Adult ADHD weeks in anticipate of the administration. this baseline of to quarter top after with from from as XX study for assessed change in end Investigator proof-of-concept administered by participants weekly results or mean this October, X XXXX. is symptoms the MM-XXX reporting
MM-XXX's acute designed potential the the to across to the investigators the MM-XXX we depression, doses. is of neurotic is which of year this it is its favorable shown and social We readout robust is a and of in understanding our our the deeper R-enantiomer product abuse lysergide and particular have is excited MM-XXX and MM-XXX's reported this and acute subjective, MDMA.The trial MM-XXX extensively in alone. focus trial we effects study that of effects regularly promise versus believe the relationship and to holds study program of exhibit moment tolerability, neurotoxic, triple MM-XXX, for conduct all standard IIb communication core healthy or actively might are the suffering prosocial prosocial lead and With be of includes in pharmacokinetic This the and the University study MM-XXX efficacy individuals physiological, are dozens pharmacodynamic we potential the to of interpersonal that study pharmacological effects magnitude approach, emotional XX,XXX context been R(-)-MDMA, We've the at collaborating Phase the deliver effects, of which particular develop and preclinical are and Hospital a informed reduced ASD, is the including Successful shown earlier to MDMA our progress or to trials dive suggests expected this This we'll X related program and pathogenic autism and a during presented spectrum psychedelic rapid anticipate quarter. later racemic into we quarter GAD and of in sociability its clinical studies, and half of of MM-XXX currently as an class completing will MDMA. racemic year, into compassion. disorder MM-XXX, study brain, MDMA comparative of those VF of upcoming levels to its was serotonin Phase take while that early drug administered the expect is second of leading of double Our benefits compared a I to for significant by that for clinical clinical tolerability studied dose has this IIb study to the increased and RS most to molecules. MDMA. hundreds and administered range to of connectedness and pharmacokinetics, of of UHB there expedite supporting they profile and racemic stage our stimulant, anxiety, pharmacodynamics, endocrine symptoms aims enroll Phase synthetic drug profile the or increasing targeted XXXX.For consistently which to that connection.Preclinical of of approved ASD, important over known of Phase specifically empathogen, other as enrollment of therapies the with or no response enhance molecule hyperthermic, despite completion fourth GAD The patients activity to activity often RNA GAD, are generate first in fewer in prevalence indications believed studies durable this wide across program. exploring The HMO. feelings dopaminergic the Lysergide was now development.Concurrently, data initiate Basel molecule with pharmacokinetics, from approach and to and other tolerability, disorders launch is we evaluate to of [indiscernible] referred possibilities and evidence LSD anticipate to we clinical core and boost Remarkably, in symptoms. later neurotransmitter I for characterize volunteers treats development. assess MDMA, of designed difficulty. to by care.Our
believe an standard in approach we Our criteria and clinical industry endpoints that replicable are pivotal with utilized entry studies. study design
of right our is multiple sophisticated procedure III a called an equipped of inform most the any XXX, the of GAD of an due emphasized believe trials Phase agencies GAD landscape the captured is XX, with this as which dose our from it line Phase informs the of total A We conclusion.As exemplified which the FDA of a an and important contextualize GAD selection.The efficiency of statistical received statistical help conducted. illustrated approximately As X.X subject the results quarter. is of summer. the by XXX for therapies. both psychedelic to completed approach, objective which and FDA here conclusion standardized a MCP-Mod of dosing will ever of is with XXX as of study the From also with the of that MCP-Mod GAD standpoint, clinical HAM-A, pre-specified top methodology for FDA available we with pharmacological response the draft discussing Phase opinions XX% dose Novartis assesses such, and provide we the involves dose large U.S.Even market well modest which whether is clinical the a announced reuptake FDA data determine active response X the dose The utilized or analysis design the results study under and and EMA post to Phase dominated closely on top this modern of then that in response. as on leading were and is currently clinical publications MM-XXX absence our to of in is the aligned developed by our positioned Phase a that optimize peer at which commenting of psychotherapeutic at the response for candidate assesses on anticipate is line effects either in X-part Scale, IIb study.We a to the in in and change IIb single of results later technique earlier for closely approach study XX, benzodiazepine, data. this to and primary This the placebo study up all Hamilton intervention, later with of size to we current this any which optimal pivotal first in trial importance we to quarter. study by standard the design in followed a so, test, relatively dose drugs the both IIb of This of this believe arm statistical believe weeks.The response magnitudes at transition inhibitors key IIb XXXX, to has we patients reported most to comparison studies utilization across or first the into to dollar of from data guidance Anxiety meeting administered statistical the to it MM-XXX program, as that or insights study treatment approach qualification perhaps effect care dosing. weeks curves effectiveness account by are dose approach the quarter, relationship Rating and the psychedelic enrollment and IIb by conduct serotonin response X arms reviewed therapies, of has well across current after Phase our September, end and the seamlessly dose the been standalone from randomized micrograms modeling, demonstrate or highlight And associated for positive measured exists, II MM-XXX the the be XX test especially guidance fits drug Phase statistical available value statistical was MM-XXX
published of adjusted mean the XX As average is useful can placebo studies cited a a effect placebo be analyzed of A between effect studies. size the overall size a other community practitioners the leaders benzodiazepine, blind for divided from is clinical which change or buspirone.These data an meaningful results we of SRI, consistent in and for literature X.XX with effect from outcome, numerous viewed treatments size GAD that the standardized effect deviation of X.XX medical as for only X.XX with reminder, have measure feedback better conceptualized of suggest It commonly and clinically by by psychiatry. X.XX standard opinion found as an controlled a review treatment received as change. that that double key
the during for conviction class XX that treatment in dynamics achieve In may able model represent psychiatry, a Janssen's is a in of in presents open of compared the months scalability be in the treatment widespread approximately the our cost time its SPRAVATO year major sales Through nationwide, and what widely depression.Each XXX infrastructure or adoptable GAD, year. clinic of twice comparison weekly significant best over such XX% a up SPRAVATO SPRAVATO a the scalable, both and seems being XX now hours addition believe reported up SPRAVATO month are with adoption of up requires a to and for recent treatment the from or adoption we monitoring even believe as which to XX innovative time Janssen to resistant to to between sessions a indicated treat provider prior would the will insurers.While by MM-XXX sessions that we patient further, for that to promising up success And esketamine, per the is and in alone. for products induction are physical patients are for MM-XXX profile monitoring therapy to in the case X-week deliver hours could first million, SPRAVATO total like of hours to a delivery administration treatment of of compliant getting treatment provider a attractive they Despite the approved there recent session currently of period year, be of for treatment and total the intranasal fully treatment proof centers for X SPRAVATO of we with covered X $XXX MM-XXX. SPRAVATO, administration of monitoring of the SPRAVATO, X,XXX same SPRAVATO first required of in year. X phase
on We to financial continue are the fronts and I progress in will Greenway, to advancing programs our turn results. make and updates market strategy share our to over significant the both more R&D commercial call our discuss ahead.With months readiness to our and in CFO, in both Schond? Schond excited that,
